Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension.
Twentysix women with pregnancy-induced hypertension have been randomly treated with either labetalol or Aldomet. A more satisfactory control of blood pressure was obtained with labetalol with minimal side-effects. After two weeks of treatment with labetalol renal function had significantly improved with a markedly lower incidence of proteinuria. More patients went into spontaneous labour following labetalol than following Aldomet; the Bishop score was also higher in this group. No adverse effects attributable to labetalol were noted in the baby either ante- or post-natally.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000378:metabolism; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy*; D007741:Labetalol / Q000008:administration & dosage / Q000627:therapeutic use*; D007743:Labor, Obstetric / Q000187:drug effects; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008750:Methyldopa / Q000627:therapeutic use*; D011188:Potassium / Q000032:analysis; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D012964:Sodium / Q000032:analysis; D014527:Uric Acid / Q000097:blood
D004983:Ethanolamines; D014527:Uric Acid; D006830:Hydralazine; D008750:Methyldopa; D012964:Sodium; D003404:Creatinine; D007741:Labetalol; D011188:Potassium